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Abstract
We adapted DELFIA
TM (dissociation-enhanced lanthanide fluoroimmunoassay), a time resolved fluorescence method, to
quantitate whole venom specific and allergenic peptide-specific IgE (sIgE), sIgG1 and sIgG4 in serum from people clinically
allergic to Australian native ant venoms, of which the predominant cause of allergy is jack jumper ant venom (JJAV). Intra-
assay CV was 6.3% and inter-assay CV was 13.7% for JJAV sIgE. DELFIA and Phadia CAP JJAV sIgE results correlated well and
had similar sensitivity and specificity for the detection of JJAV sIgE against intradermal skin testing as the gold standard.
DELFIA was easily adapted for detecting sIgE to a panel of other native ant venoms.
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Introduction
The allergic response to insect stings can range from mild skin
irritation through to large localised reactions and severe
generalised (‘‘systemic’’) reactions which can result in fatal
anaphylaxis. Insect venom allergy is a Type I or immediate
hypersensitivity, where the allergenic peptide or protein cross-links
venom-specific IgE (sIgE) bound to high-affinity IgE receptors
(FceRI) on mast cells and basophils, releasing preformed and
newly-synthesized mediators [1]. Insect stings account for up to a
third of anaphylaxis cases treated in Emergency Departments that
serve suburban and rural populations and a quarter of all
anaphylaxis deaths [2,3].
Allergy to native ants of the genus Myrmecia is an important
clinical problem in Australia. In the southern island state of
Tasmania, 1% (95% CI 0.5–1.8) of the population has experien-
ced one or more severe allergic reactions to a sting from Myrmecia
pilosula (the ‘‘jack jumper ant’’ (JJA)) [4]. The efficacy of JJA venom
immunotherapy (VIT) in preventing anaphylaxis has been
demonstrated by a randomised double-blind, placebo controlled
trial [5]. Three allergens from JJAV (Myr p 1, Myr p 2 and Myr p
3) have been identified and sequenced, including the only major
allergen, the 5608 Da heterodimer Myr p 2 [6,7,8]. Myr p 2-
specific IgE has been shown to bind to one of the chains in the
heterodimer, designated Myr p 2a [8]. Allergic reactions to the
sting of other Myrmecia species and other ant genera appear to be
less common [4,9], however the epidemiology is less well defined
due in part to lack of sensitive and specific diagnostic tests for
allergy to these species.
To diagnose specific-venom allergy, investigations to demon-
strate the presence of sIgE are used to confirm the causative
species and thus select an appropriate venom extract for VIT [10].
Methods include intradermal venom skin testing, quantitation of
sIgE in serum and functional assays such as the histamine release
test and flow-cytometry analysis of CD63 and CD203c upregula-
tion on basophils [11,12,13,14]. In vitro laboratory methods are
thought to have lower sensitivity compared to intradermal venom
skin testing [10]. For quantitation of sIgE, methods such as the
Radio-Allergosorbent test (RAST) and Enzyme-Linked Immuno-
sorbent Assay (ELISA) have evolved and been largely been
replaced by the Phadia (previously Pharmacia) CAPH assay, which
has greater sensitivity [15], and is highly automated and thus
reliable and easy to run in high throughput clinical laboratories
[16].
A recently introduced technique for highly sensitive detection
and quantitation of sIgE against peanut and dust mite allergens is
the DELFIA
TM (dissociation-enhanced lanthanide fluoroimmu-
noassay, Wallac, Turku, Finland) which utilises a time resolved
fluorescence signal [17,18]. The advantages of this method include
its log-fold dynamic range, low cost, flexibility for developing novel
assays with new allergens in small numbers of patients, and that it
does not require the use of hazardous materials such as radioactive
iodine and cyanogen bromide.
We aimed to develop and validate a DELFIA assay for
quantifying sIgE to JJAV and to the peptide allergen Myr p 2a,
and then test whether this method was easily adaptable to detect
sIgE to other native Australian ant venoms and to quantify sIgG1
and sIgG4 responses to venom immunotherapy.
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Materials
Microtitre plates 96-well, Maxisorp Nunc, Roskilde, Denmark
were obtained through In vitro Technologies Australia. Sodium
bicarbonate (S6014), Trizma hydrochloride (T3253), Sodium
chloride (S9888), Tween 20 (274348), sodium azide (S8032) and
bovine serum albumin (A3059 & A9418) were purchased from
Sigma-Aldrich, St Louis, Missouri. Anti-human IgE was pur-
chased from Bioclone, Sydney, Australia and Becton Dickinson
diagnostics, Australia. Europium-labelled streptavidin and en-
hancement solution Wallac, Oy were purchased through Perkin
Elmer, Australia.
Ethics Statement
Ethics clearances were provided by the Human Research Ethics
Committee (Tasmanian) Network (H0008934) and the South
Metropolitan Area Health Service Human Research Ethics
Committee, Fremantle Hospital, Western Australia (05/258). All
participants signed written consent forms. Ant nests were collected
with the permission of all property owners. Ethics is not required
for the collection of insects.
Participants
Allergic sera and plasma samples were taken from participants
with a history of systemic reactions to Australian native ant stings
recruited through our venom allergy clinic at Royal Hobart
Hospital or were enrolled in the Australian Ant Venom Allergy
Study (AAVAS).
For participants with suspected allergy to JJA who presented to
Royal Hobart Hospital, intradermal JJAV skin testing was
performed with a positive skin test defined by wheal growth of
at least 2 mm and flare greater than or equal to 10 mm in
response to an intradermal injection of JJAV (about 0.02 ml to
form a 3–5 mm bleb) at a concentration of 1.0 mg/ml or less. If an
initial skin test was negative, the test was repeated 3–6 weeks later
before declaring a negative result. JJA VIT was offered if the skin
test was positive and further serum and plasma samples were taken
immediately prior to commencing VIT then during VIT at
approximately 1 week, 3 weeks, 2 months, 3 months, 6 months
and 12–15 months.
Patients in the AAVAS study had reported a history of systemic
reactions to one or more ant stings. Each patient sera was screened
for sIgE to venom from ant species found in the state where the
reaction occurred, and patients who had previous exposure to ant
stings in other states of Australia were also screened for sIgE
against species endemic to this/these states.
Negative control sera and plasma were collected from healthy
volunteers in Western Australia who had recently arrived from
overseas and had never been stung by an Australian ant. To assess
the specificity of the assay in the presence of high total IgE, sera
were also obtained from patients resident in the Northern
Territory (where JJA are not endemic and thus exposure unlikely)
with a variety of atopic conditions resulting in elevated IgE.
Pooled Sera
To validate the assays, three different pooled sera were created.
One, referred to as ‘standard sera’ from this point forward, was
pooled from 21 JJAV allergic individuals with high levels of
venom-specific IgE and used to create a standard curve. The
second, referred to as ‘positive sera’ from this point forward, was
created by pooling sera from a different cohort of 24 JJAV allergic
individuals with quantifiable venom-specific IgE. The third
consisted of pooled sera from JJA venom non-allergic individuals
and was used as a negative control for all assays. Pooled sera were
aliquoted and frozen at 280uC until required.
Venom and Myr p 2a
JJAV was obtained from ants collected in Tasmania and
analysed by previously reported methods to assure consistent
allergen content prior to use [6,19]. Myr p 2a was purchased from
Proteomics International, Perth, Western Australia. Other ant
venoms of clinical significance were extracted by venom sac
dissection from ant nests collected into dry ice from all states of
Australia. These were the large 15–30 mm long ‘‘bull dog’’
Myrmecia ants (M forficata, M pyriformis, M gulosa, M gigas, M nigriceps,
M brevinoda, M simillima, M tarsata,), 10–15 mm long ‘‘jumper’’
Myrmecia ants similar in size and behaviour to the JJA (M
nigrocincta,) and the small 6 mm ‘‘greenhead ant’’ (Rhytidoponera
metallica). Prior to pooling venoms from different nests to form
reference venoms for each species, worker ants from each nest
were identified by an entomologist (Dr R W Taylor) and SDS-
PAGE was performed to confirm identical band patterns.
CAP
JJAV was coupled to CAP discs by Phadia and whole JJAV sIgE
level was performed using the Phadia CAPH system (Uppsala,
Sweden, recommended positive cut-off 0.35 IU/ml) [15] at
SouthPath Laboratories, Bedford Park, South Australia.
DELFIA for sIgE
Microtitre plates were coated with 100 mL of whole venom or
synthetic Myr p 2a at 1, 2.5, 5, 10, 15 and 20 mg/mL in coating
buffer (50 mM NaHCO3, pH 9.6) at 4uC overnight. After washing
five times with wash buffer (50 mM Tris-HCl, 0.9% NaCl, 0.05%
sodium azide, pH 7 with 0.01% Tween 20) plates were blocked
overnight with bovine serum albumin (0.5% in wash buffer) at 4uC.
After washing five times, 100 mL of sera was added in duplicate and
incubated for 2 hours at 4uC. The plates were washed (X5) and
incubated for 1 hour with 100 mL anti-human IgE (neat, 1/10,
1/20 and 1/100 in blocking buffer) at ambient temperature with
shaking. Plates were washed (X5) then incubated for 30 minutes
with 100 mL Europium-labelled streptavidin (1/1000 in blocking
buffer), at ambient temperature with shaking. Following the final
wash step, which consisted of eight washes, 100 ml enhancement
solution at 22uC was added and incubated for 5 minutes before
being read using the Wallac Victor 3 plate reader (Wallac, Oy). A
positive control (positive sera) and negative control, were run in
quadruplicate on every plate to assess reproducibility. The intra and
inter-assay precision was determined by calculation of the mean,
standard deviation and coefficient of variance of the results from
positive sera on 50 assay plates. A titration of 2-fold serial dilutions
of standard sera (1/2–1/128) was linear (R
2.0.95) and used on
every plate as an internal standard curve.
IgE Standard Curve
Calibration of the standard curve was carried out by running the
standard sera on the same plate as a set of Bioclone IgE standards
(WHO standard 2nd IRP 75/502a calibrated). A polyclonal anti
IgE antibody (Bioclone, Sydney, Australia) was used as the capture
antibody as per the standard protocol - calibrators were 91.5, 45.75,
29.4, 9.37, 3.04 and 0 IU/ml. The limit of the blank (LoB), above
which a positive result could be reported, was defined as mean plus
1.645 times the standard deviation of the negative control. The
detection limit (LoD), at which a low level of sIgE should be reliably
detected, was estimated as the mean plus two standard deviations of
the assay negative control (Table 1). Our estimate of LoD assumed
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same as for negative controls. At the time we had not yet
accumulated a suitable number of patient samples with low-level
sIgE to verify this assumption.
Applicability to Other Australian Ant Venoms
The LoB and LoD were calculated for the DELFIA sIgE assay
using other ant venoms (M forficata, M pyriformis, M gulosa, M gigas,
M nigriceps, M brevinoda, M simillima, M tarsata, M nigrocincta, and R
metallica). For determination of sIgE against these venoms, plates
were coated with 100 mlo f5 mg/ml venom and the method
described above was followed. An IgE standard curve and positive
and negative controls were included on each plate as described
above.
Applicability to JJAV and Myr p 2a specific IgG1 and IgG4
For the determination of JJAV and Myr p 2a specific IgG1 and
IgG4, the method described above for IgE was followed, except
that the anti-human IgE was replaced by anti-human IgG1 and
IgG4 (Caltag, Invitrogen, Australia at a dilution of 1/750) and sera
were diluted either 1/5 and 1/20 for IgG1 or 1/10 and 1/100 for
IgG4. Two pools of sera high in JJA and Myr p 2a specific IgG1
and high in JJA and Myr p 2a specific IgG4 were prepared and
used to create a standard curve, 1/20 to 1/1280 for IgG1 and
1/80 to 1/5120 for IgG4 and a positive control (1/20 on each
plate). IgG1 and IgG4 standard curves were calibrated against a set
of PeliClass human IgG subclass ELISA kit standards (WHO 67/
97 reference preparation) (Cell Sciences, Canton, MA, USA.). All
standard curves were linear. The pooled negative control was also
included on each plate.
Statistical Analysis
Sample means, standard deviations and variances were
calculated using Microsoft Excel. Standard curves were prepared
using linear regression in Microsoft Excel. Confidence intervals
(binomial), Spearman correlations and graphs were prepared using
Stata (Version 11) and GraphPad Prism (Version 5).
Results
Optimisation
The amount of venom and Myr p 2a peptide used for coating
assay plates was determined by titration of the venom against a
range of patient sera and found to be optimal at 5 mg/ml.
High background readings were initially a problem but this was
reduced by selectively removing/reducing background causing
reagents. For example in house wash buffer with and without
Tween 20 was trialled against the commercial wash buffer with the
in house buffer containing Tween 20 consistently showing lower
background levels. Washing was found to be a crucial factor in the
maintenance of low background levels, all washing steps consisted
of 5 aspiration/wash cycles except for the final wash prior to the
addition of the enhancement buffer which consisted of 8
aspiration/wash cycles. Various stages of the assay were found
to be highly temperature sensitive. Therefore, initial plating out of
sera was carried out with the plate on ice, while enhancement
solution was stabilised at 22uC prior to its addition. To further
reduce background readings a variety of sources of BSA were
trialled with Fraction V, protease free and essentially gamma
globulin free BSA chosen for routine preparation of blocking
buffer. A phenomenon not so easily overcome or understood was
the occurrence of so-called ‘‘hot wells’’, the random appearance of
an abnormally high count in a single well [20]. We have tried a
variety of methods to overcome this effect, including centrifuga-
tion, filtration, temperature variation of sera and the enhancement
buffer, as well as alternate buffers but, to date, nothing has
eliminated the appearance of hot wells.
The anti-human IgE from Bioclone used in this assay was tested
against the anti-human IgE antibodies from Becton Dickinson and
found to be highly sensitive at lower concentrations of IgE and was
thus chosen on this basis. The anti-human IgE antibody (Bioclone)
was titrated and found to work equally well at 1/10 dilution and
was thus used at this concentration in all experiments.
Assay calibration
A typical JJAV sIgE pooled sera standard curve is shown in
Figure 1.
Specificity in presence of high total IgE
Characteristics of the patients (n=11) whose sera were used to
determine assay specificity is shown in Table 1. They were all
found to be negative for JJAV sIgE by CAP however one was
positive for JJAV sIgE by DELFIA. In addition, sera from 23
patients who suffered severe allergic reactions following clearly
identified bulldog ant (BDA) stings in areas of Western Australia
where JJA are very uncommon were all found to be negative for
JJAV sIgE by DELFIA but positive to one or more BDA venoms.
Table 1. JJAV negative sera with high total IgE used to demonstrate assay specificity.
Sample No. Total IgE (kUA/L) Notes CAP JJAVsIgE DELFIA JJAV sIgE
08/75004 6,991 Recurrent pneumonia NEG NEG
07/262162 1,839 Probable rhinitis NEG NEG
08/41951 595 Chest infection NEG NEG
07/251692 493 Allergic rhinitis NEG NEG
08/99212 14,550 Crusted scabies NEG NEG
08/80397 19,700 Scabies protocol NEG NEG
07/232441 9,435 n/a NEG NEG
08/99214 624 Probable Allergic rhinitis NEG NEG
07/214495 584 Probable crusted scabies NEG NEG
08/099216 363 Rash/Cow’s milk allergy NEG 0.52
07/251690 3,012 Recurrent rhinosinusitis NEG NEG
doi:10.1371/journal.pone.0016741.t001
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Low intra-assay variability was shown with an average
coefficient of variance (CV) of 6.3% across 50 assays, and the
inter-assay CV was 13.7% for JJAV sIgE.
Quantitative correlation with CAP
Both CAP and DELFIA tests were performed in 145 patients in
whom 90 were positive using CAP, 84 were positive using
DELFIA and 73 were positive using both methods. Where JJAV
sIgE was detected by both assays there was a significant correlation
between JJAV sIgE measured by CAP and DELFIA (p,0.001,
Spearman’s Rank Test) (Figure 2).
Sensitivity and specificity with reference to intradermal
venom skin testing in patients with a history of reactions
to JJAV
A comparison of intradermal skin tests, CAP and DELFIA
results is presented in Table 2. Sensitivity using DELFIA was 0.69
(95%CI 0.60–0.77) and for CAP was 0.74 (95%CI 0.65–0.81).
Specificity for DELFIA was 0.96 (95%CI 0.78–1.0) and for CAP
was 1.0 (95%CI 0.85–1.0).
Applicability to JJAV and Myr p 2 a specific IgG1 and IgG4
The LoB and LoD for sIgG1 and sIgG4 assays are presented in
Table 3. Ten patients who underwent JJA VIT had a quantifiable
amount of JJAV sIgE, sIgG4 and sIgG1 against JJAV prior to
starting desensitisation. Figure 3 shows the levels of JJAV sIgE,
sIgG1 and sIgG4 increased to a peak, then sIgE decreased to
around initial levels, and IgG levels maintain a constant
concentration.
Applicability to other Myrmecia Venoms
The DELFIA has also been adapted for use with other Myrmecia
venoms. The number of sera screened, number of positives, LoB,
LoD, lower, median, and upper quartile range for positives for
each venom are shown in Table 4. The sensitivity and specificity of
these assays could not be determined for these species because
appropriately standardised venom preparations for intradermal
venom skin testing in humans were not available.
Discussion
We have developed a time-resolved fluorometric assay (DEL-
FIA) to detect JJAV sIgE, and the assay has been adapted to be
used with other native ant venoms (Myrmecia and Rhytidoponera
species), in addition to specific venom allergens (Myr p 2a) and for
the detection of JJAV specific IgG4 and IgG1. When using venom
skin testing as a diagnostic reference, sensitivities and specificities
of DELFIA were equivalent to Phadia CAP for JJAV sIgE.
Figure 1. Typical standard curve of pooled positive JJAV IgE sera standards. Standards have been calibrated against Bioclone human IgE
standard set to allow relative quantitation.
doi:10.1371/journal.pone.0016741.g001
Figure 2. Correlation of CAP versus DELFIA assays for the
determination of JJAV sIgE.
doi:10.1371/journal.pone.0016741.g002
Table 2. Sensitivity and specificity of CAP and DELFIA for
detection of sIgE for JJAV with reference to intradermal
venom skin testing.
Intradermal venom skin test result
Positive Negative
CAP Positive 90 0
Negative 32 23
DELFIA Positive 84 1
Negative 38 22
doi:10.1371/journal.pone.0016741.t002
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dynamic range, cost effectiveness and potential for high-through-
put screening. This is particularly useful for dealing with novel
allergens and in the research setting, where detection of allergen
specific IgG subclass levels may be useful. The assay has a
convenient and rapid protocol. Plates can be coated up to a week
in advance and stored at 4uC allowing batch preparation. This
results in reduced wastage of reagents, and once the plates have
been set up the assay is complete in 4.5 hours. However,
limitations of this technique include the sensitivity of the assay to
subtle temperature changes and the large number of wash cycles
that are required, although this limitation can be overcome with
automation. The ‘‘hot well’ phenomenon is a continuing problem
being the cause of many repeats [20], however, this was not the
case of more stable purified antigens such as peanut allergens[17]
or House Dust Mite allergens[18].
Intradermal venom skin testing is currently used as the gold
standard for venom allergy diagnosis as it is more sensitive for low
levels of sIgE, which is concentrated on the surface of skin mast
cells. The DELFIA and CAP were comparable for sensitivity
however some patients positive to one assay were negative to the
other and visa versa. This is probably because at low levels of sIgE
(approaching the LoB) these assays may not always reliably detect
allergen, introducing a degree of chance as to whether sIgE is
detected. Likewise in some settings a skin test may be negative and
a serum test may be positive so that the occasional case showing
Table 3. Calculated Limit of Blanks (LoB’s) and Limit of
Detection (LoD’s) for JJAV and Myr p 2a specific IgG1 and IgG4.
LoB (IU/ml) LoD (IU/ml)
JJA IgE 0.15 0.18
Myr p 2a IgE 0.09 0.12
JJA IgG1 54.8 55.9
Myr p 2a IgG1 54.4 55.8
JJA IgG4 3.7 4.5
Myr p 2a IgG4 6.4 8.2
doi:10.1371/journal.pone.0016741.t003
Figure 3. Specific IgE, IgG1 and IgG4 over a 2 year period from 10 patients undergoing VIT. A. Median values of JJAV and Myr p 2a.
B. Specific antibody levels.
doi:10.1371/journal.pone.0016741.g003
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One patient with high levels of total IgE used here (Table 1) to test
specificity, showed a positive result in the DELFIA assay. However
none of these patients have been skin tested for JJAV and it is
possible that this patient had previous exposure while resident or
visiting areas of Australia where the JJA is prevalent.
A number of patients were noted to have a higher sIgE value for
Myr p 2a compared to JJAV. The plates used in the DELFIA
assay bind venom peptides and proteins to a polystyrene solid
phase via non-covalent interactions. Given the unique charge state
of each venom peptide in the binding buffer, each will have a
different affinity for the solid phase, and therefore the venom
peptides that are bound to the solid phase may not be
quantitatively representative of whole venom. Although Myr p
2a comprises approximately half of the protein content of JJA
venom [6], it is highly basic and may have a lower affinity for the
solid phase than other venom components, which may result in a
lower proportion of it binding to the solid phase compared to what
is present in whole venom. Therefore, sera that recognise the Myr
p 2a allergen may have a significantly lower DELFIA result when
whole JJA venom is bound to the solid phase compared to Myr p
2a. This is less likely to be the case with CAP assays, where each
CAP has a higher allergen binding capacity [15]. This higher
protein binding capacity translates to a greater venom specific IgE
binding capacity, and may account for the observation that, on
average, the CAP assay determined there was more venom sIgE
present compared to the DELFIA assay. These are inherent
weaknesses to any method that utilises such solid phases with lower
protein binding capacity to bind complex allergen mixtures.
For these reasons, DELFIA is best considered a semi-
quantitative assay when being used to compare the relative
amount of venom specific IgE, IgG1 and IgG4 between individuals
or changes in individual patients over time, but in the context of
diagnosing the presence of IgE antibodies, it produces similar
results compared to CAP with respect to sensitivity and selectivity.
The DELFIA has proved a useful tool for measuring JJAV sIgE
in patient sera and plasma and it is easily adaptable to be used to
detect IgE specific for venom peptide allergens and other ant
venoms and for measuring venom specific IgG1 and IgG4.
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